Biomea Fusion Change in Accounts Payable 2020-2025 | BMEA

Biomea Fusion change in accounts payable from 2020 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.

Biomea Fusion Change in Accounts Payable 2020-2025 | BMEA

Biomea Fusion change in accounts payable from 2020 to 2025. Change in accounts payable can be defined as the increase or decrease in trade payables for the given period.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$231.3B
Amgen (AMGN)$153.3B
Gilead Sciences (GILD)$137.2B
Vertex Pharmaceuticals (VRTX)$96.3B
Bristol Myers Squibb (BMY)$92.3B
CSL (CSLLY)$83.7B
GSK (GSK)$76.6B
Regeneron Pharmaceuticals (REGN)$60.4B
Alnylam Pharmaceuticals (ALNY)$57B
Argenex SE (ARGX)$41.1B
BioNTech SE (BNTX)$26.8B
Royalty Pharma (RPRX)$20.8B
Insmed (INSM)$20.7B
Biogen (BIIB)$18.7B
Incyte (INCY)$15.3B
Illumina (ILMN)$14.7B
Genmab (GMAB)$14.6B
Genmab (GNMSF)$14.3B
Ascendis Pharma (ASND)$11.6B
BioMarin Pharmaceutical (BMRN)$11.4B
QIAGEN (QGEN)$10.7B
Swedish Orphan Biovitrum (BIOVF)$10.6B
Moderna (MRNA)$10.4B
Exelixis (EXEL)$10.1B
Verona Pharma American Depositary Share (VRNA)$9B
Blueprint Medicines (BPMC)$8.3B
Exact Sciences (EXAS)$8.2B
Bio-Techne Corp (TECH)$7.9B
Roivant Sciences (ROIV)$7.9B
Halozyme Therapeutics (HALO)$7.7B